JMS-17-2
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells[1].
Product Specifications
CAS Number
1380392-05-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CX3CR1
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/jms-17-2.html
Purity
99.59
Solubility
DMSO : 41.67 mg/mL (ultrasonic)
Smiles
O=C1C2=CC=CN2C3=C(C=CC=C3)N1CCCN4CCC(C5=CC=C(Cl)C=C5)CC4
Molecular Formula
C25H26ClN3O
Molecular Weight
419.95
Precautions
H302, H315, H319, H335
References & Citations
[1]Shen F, et al. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14 (6) :518-27.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471870-100 1x 100 µL
CD10 (Membrane Metalloendopeptidase) (MME/1870), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
